Smith & Nephew (LON:SN) Given Neutral Rating at UBS Group

Smith & Nephew (LON:SN)‘s stock had its “neutral” rating reaffirmed by UBS Group in a report released on Tuesday,Digital Look reports. They presently have a GBX 1,300 target price on the stock. UBS Group’s target price points to a potential upside of 13.34% from the stock’s current price.

A number of other equities research analysts also recently issued reports on SN. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 1,350 price target on shares of Smith & Nephew in a report on Tuesday, March 17th. Berenberg Bank reissued a “hold” rating and issued a GBX 13 price target on shares of Smith & Nephew in a report on Friday. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of GBX 1,185.86.

Smith & Nephew Trading Up 0.9%

Shares of Smith & Nephew stock opened at GBX 1,147 on Tuesday. The stock has a market capitalization of £12.57 billion, a P/E ratio of 41.30, a price-to-earnings-growth ratio of 0.46 and a beta of 0.74. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57. The stock has a 50-day moving average price of GBX 1,243.05 and a 200-day moving average price of GBX 1,260.50.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.